8UPB
De novo designed IL-6 mimetic
8UPB の概要
| エントリーDOI | 10.2210/pdb8upb/pdb |
| 分子名称 | De novo designed IL-6 mimetic (2 entities in total) |
| 機能のキーワード | cytokine, de novo design |
| 由来する生物種 | synthetic construct |
| タンパク質・核酸の鎖数 | 1 |
| 化学式量合計 | 7826.06 |
| 構造登録者 | |
| 主引用文献 | Huang, B.,Coventry, B.,Borowska, M.T.,Arhontoulis, D.C.,Exposit, M.,Abedi, M.,Jude, K.M.,Halabiya, S.F.,Allen, A.,Cordray, C.,Goreshnik, I.,Ahlrichs, M.,Chan, S.,Tunggal, H.,DeWitt, M.,Hyams, N.,Carter, L.,Stewart, L.,Fuller, D.H.,Mei, Y.,Garcia, K.C.,Baker, D. De novo design of miniprotein antagonists of cytokine storm inducers. Nat Commun, 15:7064-7064, 2024 Cited by PubMed Abstract: Cytokine release syndrome (CRS), commonly known as cytokine storm, is an acute systemic inflammatory response that is a significant global health threat. Interleukin-6 (IL-6) and interleukin-1 (IL-1) are key pro-inflammatory cytokines involved in CRS and are hence critical therapeutic targets. Current antagonists, such as tocilizumab and anakinra, target IL-6R/IL-1R but have limitations due to their long half-life and systemic anti-inflammatory effects, making them less suitable for acute or localized treatments. Here we present the de novo design of small protein antagonists that prevent IL-1 and IL-6 from interacting with their receptors to activate signaling. The designed proteins bind to the IL-6R, GP130 (an IL-6 co-receptor), and IL-1R1 receptor subunits with binding affinities in the picomolar to low-nanomolar range. X-ray crystallography studies reveal that the structures of these antagonists closely match their computational design models. In a human cardiac organoid disease model, the IL-1R antagonists demonstrated protective effects against inflammation and cardiac damage induced by IL-1β. These minibinders show promise for administration via subcutaneous injection or intranasal/inhaled routes to mitigate acute cytokine storm effects. PubMed: 39152100DOI: 10.1038/s41467-024-50919-4 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (1.48 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






